Latest news

Extension of preclinical research collaboration agreement with a top-10 large pharma company

Posted on Jun 15, 2018

Oslo (Norway), 15 June 2018 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company, initiated in September 2015. The extended evaluation period spans over 6 months, until the end of December 2018, and may be further extended. The […]

Minutes from Annual General Meeting 2018

Posted on May 29, 2018

Oslo, 29 May 2018. The Annual General Meeting in PCI Biotech Holding ASA took place today, 29 May 2018. All proposals in the call were approved. The Board of Directors consists of the following members until the next Annual General Meeting:   * Hans Peter Bøhn, chairman   * Hilde H. Steineger, member   * […]

Disclosure of voting rights for Chairman of the Board

Posted on May 28, 2018

Oslo, 28 May 2018. PCI Biotech Holding ASA (“PCI Biotech” or the “Company”) issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and shall open the annual general meeting of the Company on 29 May 2018. Mr. Bøhn holds 83,556 shares, representing 0.3 per cent […]